Gut Microbiota in Patients With Urolithiasis
Launched by HOSPITAL REGIONAL DE ALTA ESPECIALIDAD DE LA PENÍNSULA DE YUCATÁN · Aug 19, 2022
Trial Information
Current as of August 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific diet affects the gut bacteria of adults who have kidney stones, also known as urolithiasis. Researchers want to find out if controlling the intake of certain foods—those high in oxalates (which can promote stone formation) and those high in citrates (which can help prevent stones)—can change the gut microbiota. This is important because the gut bacteria play a role in our overall health and may influence the development of kidney stones.
To participate in the trial, individuals must be between 18 and 60 years old, live in Merida, Yucatan, and have been diagnosed with kidney stones. They should also have a body mass index (BMI) between 25 and 39.9 and not have taken certain supplements or antibiotics recently. Participants can expect to follow a dietary plan aimed at reducing kidney stone risk while the researchers monitor changes in their gut bacteria. Overall, this study aims to find new strategies to help reduce kidney stones and their complications, such as chronic kidney disease.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Subjects living in Merida, Yucatan
- • Female or male
- • Age between 18 and 60 years
- • Confirmed diagnosis of UL confirmed with ultrasound (≥5mm) and/or radiographs or who had expelled a stone in a time no longer than 7 days at the time of selection
- • BMI ≥ 25 and ≤ 39.9 kg/m2; no antibiotic intake (last 30 days)
- • No intake of probiotics, prebiotics or synbiotics (last 15 days)
- • No intake vitamin C supplements (last 15 days)
- • No intake calcium supplements (last 15 days)
- Exclusion criteria:
- • Previous medical diagnosis of chronic kidney disease
- • Serum creatinine \>1.2 mg/dL
- • Glomerular filtration \<60 mL/min or 130 mL/min
- • Type 2 diabetes
- • Renal tubular acidosis
- • Pregnancy
- Elimination criteria:
- • Not meeting 80% adherence to treatment
- • Antibiotic consumption during the intervention
About Hospital Regional De Alta Especialidad De La Península De Yucatán
The Hospital Regional de Alta Especialidad de la Península de Yucatán is a leading clinical research institution dedicated to advancing healthcare through innovative research and high-quality patient care. With a focus on specialized medical services, the hospital actively engages in clinical trials that aim to improve treatment outcomes and enhance the understanding of various health conditions. Committed to ethical research practices and collaboration with national and international partners, the hospital fosters an environment of scientific inquiry and excellence, ensuring that the latest medical advancements are translated into effective patient therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mérida, Yucatán, Mexico
Mérida, , Mexico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials